Effect of anti-VEGF therapy for myopic choroidal neovascularization in persons under 50 years of age Yuta Usui 1 , Takayoshi Sumioka 1 , Hiroki Iwanishi 1 , Shizuya Saika 1 1Department of Ophthalmology, Wakayama Medical University pp.793-799
Published Date 2019/6/15
DOI https://doi.org/10.11477/mf.1410213178
  • Abstract
  • Look Inside
  • Reference

Abstract Purpose:To report outcome of anti-VEGF(vascular endothelial growth factor)therapy for patients under 50 years old with myopic choroidal neovascularization(mCNV).

Subject and Method:The subjects are 6 eyes of 6 patients under the age of 50 visiting our department of eye optics from April 1, 2012 to March 31, 2018. Treatment was performed at the time of introduction of ranibizumab vitreous injection(IVR)or aflibercept vitreous injection(IVA). We examined retrospectively the visual acuity before and after treatment, thickness of the fovea reticularis thickness, and the number of anti VEGF medication administration.

Results:The average age was 34.5±9.7 years, the gender was 1 male and 5 females. The average administration frequency of anti-VEGF was 2.8±2.8 times. Pre-treatment visual acuity(log MAR)was 0.16±0.24, and post-treatment visual acuity was 0.03±0.25. Pretreatment fovea central reticulum thickness was 309.7±76.9, post-treatment foveal net thickness was 246.5±49.8. Improvement or deterioration of changes of 2 or more stages was 3 cases of improvement, 2 cases of invasion, 1 case of deterioration.

Conclusion:Except for one case in which CNV was located under the fovea, visual prognosis of myopic CNV patients under the age of 50 was good.

Copyright © 2019, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院